Clinical Trials and Research

BackgroundConduction system disorders and arrhythmias may require pacemaker (PM) or implantable cardioverter-defibrillator implantation in transthyretin amyloid…

AbstractBackgroundTransthyretin amyloid cardiomyopathy (ATTR-CM) is more often diagnosed in men than in women but sex-specific data remain limited.ObjectivesThe…

AbstractAcoramidis is a novel transthyretin stabilizer recently approved for the treatment of transthyretin amyloid cardiomyopathy. Although clinical trials showed…

Aims To evaluate the applicability of the RoMa classification in patients with transthyretin cardiac amyloidosis (ATTR-CM) and to assess its association with…

AbstractBackground: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive infiltrative cardiomyopathy associated with substantial morbidity and mortality…

Background and Objectives: Amyloidosis is a systemic disorder characterized by extracellular deposition of misfolded protein fibrils, most commonly light-chain (AL…

AbstractIntroductionIgD-associated AL amyloidosis is a rare subtype, accounting for 1–2% of cases, with fewer than 100 reported. Prior studies show inconsistent…

AbstractBackgroundTransthyretin cardiac amyloidosis (ATTR-CM) is a progressive, underdiagnosed cause of heart failure (HF). Diagnostic delays may increase cardiac…

AbstractBACKGROUND:Technetium-based cardiac amyloid radionuclide imaging enables noninvasive diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM), but…

Long-term treatment with the experimental therapy candidate cliramitug safely and effectively reduces toxic clumps of the transthyretin (TTR) protein and heart…